Annual report pursuant to Section 13 and 15(d)

Schedule of Identifiable Intangible Assets Carrying Value (Details)

v3.22.1
Schedule of Identifiable Intangible Assets Carrying Value (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Finite-lived Intangible Assets, Gross $ 39,251 $ 39,251
Finite-Lived Intangible Assets, Accumulated Amortization (31,964) (27,900)
Finite-Lived Intangible Assets, Net $ 7,287 11,351
CLIA Lab [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 2 years 3 months 18 days  
Finite-lived Intangible Assets, Gross $ 609 609
Asuragen Acquisition [Member] | Thyroid [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 9 years  
Finite-lived Intangible Assets, Gross $ 8,519 8,519
RedPath Acquisition [Member] | Pancreas Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 7 years  
Finite-lived Intangible Assets, Gross $ 16,141 16,141
RedPath Acquisition [Member] | Barrett's Test [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 9 years  
Finite-lived Intangible Assets, Gross $ 6,682 6,682
BioPharma Acquisition [Member] | Trademarks [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 10 years  
Finite-lived Intangible Assets, Gross $ 1,600 1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Asset, Useful Life 8 years  
Finite-lived Intangible Assets, Gross $ 5,700 $ 5,700